Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Recent large-scale studies demonstrate that high-sensitivity C-reactive protein (hsCRP) is a potent, stable predictor of cardiovascular events, even in individuals without traditional risk factors. Despite its clinical utility in improving
The nationwide SCD‑PROTECT study (n=19,598) found substantial early risk of sustained VT/VF in newly diagnosed ischaemic and non‑ischaemic cardiomyopathy; wearable cardioverter‑defibrillators (WCDs) delivered life‑saving therapy with low in
ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑relat
In VESALIUS-CV, evolocumab reduced first major adverse cardiovascular events by ~25% (HR 0.75) versus placebo in patients with atherosclerosis or diabetes without prior myocardial infarction or stroke, with modest absolute risk reductions a
In a Swedish cohort of 24,791 adults aged 50–64, adding CCTA-derived measures of coronary atherosclerosis to pooled cohort equations and coronary artery calcium score modestly improved prediction of first coronary events over ~8 years.
In the VESALIUS‑CV trial, evolocumab reduced first major adverse cardiovascular events by 25% (3‑point MACE) and 19% (4‑point MACE) versus placebo over 4.6 years in patients with atherosclerosis or diabetes and no prior MI or stroke.
This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for thos